Speciality
Spotlight

 



 


Orthopaedics


 

 


Osteoporosis
       

  • Effect of 
    Alendronate on Risk of Fracture in Women with
    Low Bone Density but Without Vertebral Fractures:
    Results from the Fracture Intervention Trial.
    SR Cummings, for the Fracture
    Intervention Trial Research Group (Univ of Calif, San Francisco; Merck Research
    Labs, Rahway, NJ; Univ of Tenn, Memphis; et al)
    JAMA 280: 2077-2082, 1998.
        
    Conclusion of the study was
    Alendronate safely increased bone mineral density and
    decreased the risk of first vertebral deformity in
    women with low bone mineral density but without
    vertebral fracture.  Among women with
    osteoporosis, alendronate significantly reduced the
    risk of clinical fractures; however, this was not seen
    in women with higher bone mineral density.
         
    Editorial comment: This
    randomized controlled trial provides much useful
    information about the effects of alendronate on bone
    density and fracture risk. 
    A group of postmenopausal women without
    evidence of vertebral fracture were treated with
    alendronate or placebo for 4 years. 
    A significantly reduced risk of osteoporotic
    fractures with alendronate occurred only among those
    women who had evidence of osteoporosis before entering
    the study, not those without osteoporosis. 
    Estrogen remains the best therapy for
    prevention or treatment of osteoporosis. 
    Estrogen has additional health benefits, but
    alendronate only prevents the progression of
    osteoporosis.  Also unlike
    estrogen, which has been shown to maintain bone
    preservation for decades studies with alendronate have
    been limited to 4 years. 
    Thus, alendronate should only be used to treat
    osteoporosis among women who have contraindications or
    who are unwilling to take estrogen.
               



 

         

Speciality Spotlight

 

 

Osteoporosis
       

  • Effect of  Alendronate on Risk of Fracture in Women with Low Bone Density but Without Vertebral Fractures: Results from the Fracture Intervention Trial.
    SR Cummings, for the Fracture Intervention Trial Research Group (Univ of Calif, San Francisco; Merck Research Labs, Rahway, NJ; Univ of Tenn, Memphis; et al)
    JAMA 280: 2077-2082, 1998.
        
    Conclusion of the study was Alendronate safely increased bone mineral density and decreased the risk of first vertebral deformity in women with low bone mineral density but without vertebral fracture.  Among women with osteoporosis, alendronate significantly reduced the risk of clinical fractures; however, this was not seen in women with higher bone mineral density.
         
    Editorial comment: This randomized controlled trial provides much useful information about the effects of alendronate on bone density and fracture risk.  A group of postmenopausal women without evidence of vertebral fracture were treated with alendronate or placebo for 4 years.  A significantly reduced risk of osteoporotic fractures with alendronate occurred only among those women who had evidence of osteoporosis before entering the study, not those without osteoporosis.  Estrogen remains the best therapy for prevention or treatment of osteoporosis.  Estrogen has additional health benefits, but alendronate only prevents the progression of osteoporosis.  Also unlike estrogen, which has been shown to maintain bone preservation for decades studies with alendronate have been limited to 4 years.  Thus, alendronate should only be used to treat osteoporosis among women who have contraindications or who are unwilling to take estrogen.
               

 

By |2022-07-20T16:44:12+00:00July 20, 2022|Uncategorized|Comments Off on Osteoporosis

About the Author: